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Summary
Primary hypoparathyroidism not only occurs as an isolated id-
iopathic autoimmune disease (idiopathic hypoparathyroidism)
but also as a component disease within the scope of autoim-
mune polyendocrinopathy-candidiasis-ectodermal dystrophy
(APECED). Hypoparathyroidism constitutes the major en-
docrine component disease in APECED occurring in 80-90%
of patients and manifests during childhood. The inheritance of
APECED, monogenic and autosomal-recessive, is due to a de-
fect in a single gene, called autoimmune regulator gene (AIRE)
which has been identified in 1997 and mapped to chromo-
some 21. So far, 45 different mutations have been detected
throughout the entire coding region of the AIRE gene. Two
mutations in exon 6 (R257X) and exon 8 (13-bp deletion), oc-
cur most frequently in European and North American popula-
tions, respectively. They are responsible for the expression of
a truncated autoimmune regulator protein. There is evidence
that the AIRE protein has a central role in maintenance of im-
mune tolerance. It has multiple domains which are discussed
to be involved in transcriptional activity, nuclear transport,
DNA binding, and homomultimerization. Mutational analysis
of AIRE gene allows to identify patients at risk for APECED.
On the other hand, it can help to distinguish patients with
APECED from those with isolated hypoparathyroidism, and
thereby, avoiding family members not having APECED of un-
necessary follow-up. However, the absence of a mutation in
the AIRE gene does not exclude the APECED. Therefore, diag-
nosis is dependent on the determination of the clinical picture
of the syndrome. 
KEY WORDS: genetics, autoimmune hypoparathyroidism, AIRE gene.
Clinical aspects of hypocalcaemia
Hypoparathyroidism manifests with hypocalcaemia which is as-
sociated with reduced parathyroid hormone (PTH) secretion
from parathyroid glands due to disease or surgical damage to
the parathyroids. PTH may mobilize calcium from bone and in-
crease the resorption over the kidney (Brandi et al., 1998).
Hypocalcaemia leads to alterations in neuromuscular function.
Major symptoms are paraesthesia around mouth and in fin-
gers, muscle cramps, and seizures. In addition, tetany (involun-
tary muscle contraction) may occur in hands resulting in car-
popedal spasm. Chronic hypocalcaemia leads to calcification
of the basal ganglia of the brain and involves the development
of cataracts. For anticipation of incipient tetany, the Chvostek’s
sign can be used which is elicited by tapping the facial nerve
immediately after it exits from the auditory canal. Tetany can
also be predicted by Trousseau’s sign (Brandi et al., 1998). For
this, a blood-pressure cuff is maintained for ten minutes at 3
mmHg above the systolic pressure. Patients with Trousseau’s
sign show spasmodic contraction of the small muscles of the
hand (carpopedal spasm). The final diagnosis of hypocal-
caemia comprises the consideration of the clinical setting as
well as the measurements of serum calcium and phosphate
concentrations. Successful treatment usually implies adminis-
tration of calcium intravenously or orally, depending on the ur-
gency for a rapid response as well as the treatment with a
short-acting vitamin D metabolite, for the most part 1,25-dihy-
droxyvitaminD. 
The extracellular calcium concentration is measured by the cal-
cium sensing receptor (CaSR) which is widely expressed in
several tissues and is located in the plasma membrane of the
cell. It functions as a sensor for extracellular calcium concen-
tration and regulates the secretion of the PTH in dependence
on changing extracellular calcium values (Pearce et al., 1996).
Thus, stable calcium concentration can be maintained. The
CaSR was recently reported to be an autoantigen in hy-
poparathyroidism. Several mutations in the gene for the CaSR
have been described. Some mutations inactivate CaSR caus-
ing familial hypocalciuric hypercalcemia, whereas other muta-
tions activate CaSR resulting in autosomal dominant hypocal-
cemia (Thakker, 2001). 
Hypoparathyroidism
Primary hypoparathyroidism occurs both as an isolated so-
called idiopathic autoimmune disease (idiopathic hypoparathy-
roidism) as well as within the scope of the autoimmune polyg-
landular syndromes (APS). Idiopathic hypoparathyroidism is
present in over 80% of patients. Most patients are character-
ized by acquired hypoparathyroidism due to surgery or autoim-
mune etiology. In addition, familial forms of congenital and ac-
quired hypoparathyroidism have been described which arise
from gene defects. These hereditary forms of hypoparathy-
roidism are of various genetic origin (Tab. I). They comprise fa-
milial syndromes with multiple organ system abnormalities or
isolated familial syndromes with different modes of inheritance,
all being accompanied by hypoparathyroidism (Ahn et al.,
1986; Thakker et al., 1990; Parkinson and Thakker, 1992).
With respect to multisystem abnormalities, the parathyroid
gland abnormalities are not intrinsic to defects within the
parathyroid gland but are otherwise secondary to other devel-
opments or regulatory abnormalities. For example, the DiGe-
orge syndrome (caused by a gene defect: 22q11 deletion)
comprises several developmental disorders which are centered
 the third and fourth branchial pouches. It is characterized by
partial or complete hypoparathyreoidism as a result of congeni-
tal absence or hypoplasia of the parathyroid glands, a T-cell
deficiency due to partial or incomplete development of the thy-
Clinical Cases in Mineral and Bone Metabolism 2004; 1(2): 113-116 113
Genetics of autoimmune hypoparathyroidism
Mini-review
FOR
 REV
IEW 
ONL
Y
© CI
C ED
IZION
I INT
ERN
AZIO
NALI
mus gland, cardiac and conotruncal defects, and craniofacial
abnormalities. There are both sporadic and inherited forms to
be found. Hypoparathyroidism is further associated with anoth-
er rare familial multiple organ system failure, called autoim-
mune polyendocrinopathy-candidiasis-ectodermal dystrophy
(APECED), also denominated as autoimmune polyen-
docrinopathy syndrome type 1 (APS1).
Hypoparathyroidism associated with autoimmune polyen-
docrinopathy-candidiasis-ectodermal dystrophy
Clinical manifestation: Hypoparathyroidism is the most com-
mon endocrine component disease in APECED which is a
combination of several distinct disorders affecting mainly en-
docrine glands being characterized by immune-mediated de-
struction of endocrine tissues. It is characterized by the concur-
rently presence of at least two of the following three features:
hypoparathyroidism (failure of the parathyroid glands which
control calcium), candidiasis (yeast infection), and adrenal in-
sufficiency (failure of the adrenal gland) (Ahonen et al., 1990).
Most patients with APECED develop hypoparathyroidism (Fig.
1). This autoimmune disease is characterized by the autoim-
mune destruction of the parathyroid gland and adrenal gland.
T-cell abnormalities lead to mucocutaneous candidiasis. High-
est incidence for developing hypoparathyroidism occurred be-
tween 10 and 15 years of age (Gylling et al., 2003). Further en-
docrinopathies such as type 1 diabetes, gonadal dysfunction,
autoimmune thyroid disease or autoimmune hepatitis may be
also present leading to variable combinations of component
diseases (Dittmar and Kahaly, 2003, 2004 submitted; Kahaly
and Dittmar, in press). Non-endocrine diseases such as dystro-
phies of ectodermal structures (keratopathy and dystrophy of
dental enamel and nails), alopecia, vitiligo, autoimmune gastri-
tis, and pernicious anemia are frequently present (Ahonen et
al., 1990; Perheentupa, 1996). Hypoparathyroidism and muco-
cutaneous candidiasis are generally manifest during childhood,
whereas the onset of autoimmune adrenal insufficiency occurs
in early adolescence. Further component diseases may appear
throughout adulthood. The phenotype of APECED varies wide-
ly. APECED patients show defective tolerance to certain self-
antigens. Various other autoantigens have been observed (Ui-
bo et al., 1994; Perniola et al., 2000; Betterle et al., 2002), but
circulating autoantibodies against parathyroid gland have been
difficult to demonstrate. Antibodies against CaSR have been
observed in 35% of patients with APECED (Li et al., 1996),
whereas other authors did not find differences versus controls
(Gylling et al., 2003). APECED has a penetrance of 100% and
does not display female preponderance. 
Immunogenetics: Contrary to other autoimmune diseases, the
genetic basis of APECED is monogenic with autosomal-reces
sive inheritance (Ahonen, 1985). It is due to a defect in a single
gene which has been identified in 1997, mapped to chromo-
some region 21q22.3, and denominated as autoimmune regu-
lator (AIRE) gene (Bjorses et al., 1996; Nagamine et al., 1997;
Finnish-German APECED Consortium, 1997; Aaltonen et al.,
1997; Chen et al., 1998). The AIRE gene has 14 exons span-
ning 11.9 kb of genomic DNA (Nagamine et al., 1997). So far,
45 different mutations have been published throughout the en-
tire coding region of the AIRE gene (Pearce et al., 1998; Wang
et al., 1998). These are deletions, insertions, and substitutions
(Heino et al., 2001; Meloni et al., 2002). Many mutations are
frameshift or nonsense mutations. Different mutations have
varying effects on thein vitro function of the AIRE protein
(Halonen et al., 2004). Nine mutations in the AIRE gene were
found in patients with APECED (Finnish-German APECED
Consortium, 1997; Nagamine et al., 1997; Scott et al., 1998;
Rosatelli et al., 1998). Two mutation hotspots occur: R257X in
exon 6 and 13-bp deletion (13-bpdel) in exon 8 (Fig. 2) which
are the most frequent mutations in European populations. For
both mutations, different haplotypes have been observed giv-
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Table I - Overview of familial hereditary forms of hypoparathyroidism.
Hypoparathyroidism with multiple organ system abnormalities
•  Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) 
•  DiGeorge syndrome
•  Renal dysgenesis /sensorineural deafness syndromes
Isolated non-autoimmune hypoparathyroidism syndromes 
•  X-linked hypoparathyroidism
•  Autosomal recessive syndromes (PTH gene intron splice site mutation)
•  Autosomal dominant syndromes (PTH signal peptide mutation; calcium receptor mutations)
PTH, parathyroid hormone.
Figure 1 - Prevalence of endocrine and non-endocrine component dis-
eases in patients with autoimmune polyendocrinopathy-candidiasis-ec-
todermal dystrophy (APECED). Abbreviations: adrenal; Addisons’s dis-
ease; candidiasis, mucocutaneous candidiasis; diabetes, type 1 dia-
betes mellitus; gonadal, gonadal failure; hepatitis; chronic active hepati-
tis; parathyroid, hypoparathyroidism; malabs., malabsorption syn-
dromes; pern., pernicious anemia; pituitary, hypopituitarism; thyroid,
thyroid disease. 
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ing evidence to independent origins. The R257X is a C to T
transition being responsible for the expression of a truncated
regulator protein. The 13-bp-del is characterized by a deletion
of 13 nucleotides in exon 8 of the AIRE gene causing a
frameshift mutation resulting in a truncated protein. R257X is
the predominant mutation in Finnish and northern Italian pa-
tients. It has been found in 83% of alleles studied in Finnish pa-
tients with APECED (Nagamine et al., 1997) as well as in
Swiss, northern Italian, and eastern European patients (Scott
et al., 1998; Cihakova et al., 2001). In contrast, the 13-bpdel is
the major mutation in Anglo-American and Norwegian patients,
accounting for more than 70% of mutant alleles in United King-
dom and 53% of North American patients with APECED (Wang
et al., 1998; Nithiyananthan et al., 2000). In addition, specific
mutations have been observed in geographically more isolated
regions. For example, a single Sardinian mutation (R139X,
arg139-to-ter) in exon 3 of the AIRE gene was responsible for
19 of 21 Sardinian AIRE alleles in patients with APECED and
has not been found in other populations (Rosatelli et al., 1998).
There is evidence for some association between the type of
mutation in the AIRE gene and the APECED phenotype. In this
context, the frequency of hypoparathyroidism is lower in pa-
tients with the R257X allele in homozygous form than in pa-
tients without the allele (83% versus 94%) (Halonen et al.,
2002). 
The AIRE gene is expressed in immunologically relevant tis-
sues, primarily in the thymus medulla, in lymph nodes and
CD14-positive monocytes, but not in CD4-positive T cells
(Pitkänen et al., 2001; Kogawa et al., 2002). It encodes the
AIRE autoimmune regulator protein that contains 545 amino-
acids (Nagamine et al. 1997). It is probably a central protein in
the maintenance of immune tolerance and comprises multiple
domains which might be involved in transcriptional activity, nu-
clear transport, DNA binding, and homomultimerization (Halo-
nen et al., 2004). It contains two plant homeodomain (PHD)
type zinc fingers, four nuclear receptor binding LXXLL motifs, a
putative DNA-binding domain denominated SAND as well as a
highly conserved N-terminal domain which is similar to the ho-
mogeneously staining region domain of the Sp100 protein
(Pitkanen and Peterson, 2003). This important DNA binding
molecule has structural domains that are characteristic for tran-
scription regulators (Meloni et al., 2002). The AIRE expression
in chondrocytes which were derived from human fetal growth
plates as well as primary culture of human chondrocytes gave
evidence for a potential impact of abnormal AIRE expression in
the development of reversible metaphyseal dysplasia in
APECED (Harris et al., 2003).
There is evidence that the phenotype of APECED is modified by
other genetic factors (Halonen et al., 2002). However, recent
data did not show any associations of the HLA class II DRB1,
DQA1, and DQB1 alleles with hypoparathyroidism in patients
with APECED (Gylling et al., 2003). The finding that most pa-
tients with hypoparathyroidism are males indicates that sex may
modify the phenotype of APECED (Gylling et al., 2003).
The AIRE can be considered as a key toward the understand-
ing of the molecular pathogenesis of APECED promoting the
ability for molecular diagnosis. Mutational analysis of AIRE is
important to identify patients at risk for APECED. In particu-
lar, genetic diagnosis of APECED is important to distinguish
patients with isolated hypoparathyroidism from those who
overlap with the phenotype of APECED, because it avoids
family members not having APECED of unnecessary follow-
up. However, the absence of a mutation in the AIRE gene
does not exclude the APECED. Therefore, diagnosis is de-
pendent on the determination of the clinical picture of the syn-
drome (Perheentupa, 2002). The etiology of hypoparathy-
roidism of APECED is still unknown. One should study
whether the AIRE gene is expressed in the human parathy-
roid, because its absence could be a pathogenetic factor
(search for AIRE mRNA in the parathyroid). 
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